ACADSB

ACADSB (Acyl-CoA Dehydrogenase, Short/Branched Chain) may not be a household name. Still, its role in metabolism is critical to patient health and has a significant impact on those with metabolic disorders. 

As an enzyme involved in breaking down branched-chain amino acids (especially isoleucine), ACADSB directly impacts energy production and overall metabolic function. 

ACADSB malfunctions can lead to serious conditions like Isobutyryl-CoA Dehydrogenase Deficiency (IBDD), causing symptoms ranging from muscle weakness to metabolic crises. 

Understanding how ACADSB works and when to test for its dysfunction is essential for clinicians who want to make timely, informed treatment decisions. 

What is ACADSB?

ACADSB, or Acyl-CoA Dehydrogenase, Short/Branched Chain, plays an important role in breaking down fatty acids and branched-chain amino acids like isoleucine. It is located in the mitochondria, the parts of the cell responsible for producing energy. 

It also contributes to beta-oxidation in the mitochondria, the process by which fatty acids are broken down to produce energy.

In normal cells, ACADSB helps process fats and amino acids from food. The body then uses these processed molecules to create energy, especially when more energy is needed. ACADSB also plays a role in managing triglyceride (TG) and cholesterol (CHOL) levels, which are important for maintaining healthy cell functions.

When ACADSB functions properly, it supports overall metabolic health by ensuring that fatty acids and amino acids are broken down efficiently to provide energy. 

Mutations in the ACADSB gene can cause metabolic disorders, most notably SBCAD Deficiency. This condition impairs the body's ability to metabolize the amino acid isoleucine and can result in toxic buildup of intermediates, leading to severe health issues.

Deficiencies are inherited in an autosomal recessive pattern, meaning both parents must carry a mutation for a child to be affected.

SBCAD Deficiency (2-Methylbutyryl-CoA Dehydrogenase Deficiency)

SBCAD Deficiency (also known as 2-methylbutyryl-CoA dehydrogenase deficiency) is a rare autosomal recessive disorder involving isoleucine metabolism. It is caused by mutations in the ACADSB gene. This condition is most common in the Hmong Chinese population but can also be found in other groups.

The clinical impact of SBCAD deficiency is still not fully understood, as the condition is often detected in asymptomatic individuals. Some symptomatic cases, particularly among Hmong individuals, have experienced neurological issues like seizures and developmental delay.

Symptoms of SBCAD deficiency (SBCADD) can include:

• Poor feeding
• Lethargy
• Vomiting
• Irritability
• Dyspnea (difficulty breathing)
• Seizures
• Coma
• Poor growth
• Muscle weakness
• Delayed motor skills development
• Intellectual disability

However, most individuals with SBCADD (including those detected via newborn screening) do not develop symptoms and remain asymptomatic.  

However, many screened individuals have remained healthy, suggesting that SBCAD deficiency may not always lead to disease and might only be a biochemical marker. Long-term follow-up of these patients is necessary better to understand the full clinical spectrum of the disorder.

Currently, there is no definitive therapy for SBCAD deficiency, and dietary restrictions may not be necessary for most patients. Further studies will help clarify the need for treatment and long-term management.

Who Should Get ACADSB Tested?

The following groups may benefit from genetic testing for ACADSB status:

Individuals with Metabolic Symptoms

If a patient exhibits symptoms like muscle weakness, developmental delays, or recurrent episodes of metabolic acidosis, testing for ACADSB deficiencies may be necessary. Early detection can prevent complications by allowing clinicians to implement dietary or medical interventions that address the metabolic dysfunction.

Patients with Family Histories of Metabolic Disorders

Genetic testing for ACADSB mutations is particularly important for individuals with a family history of inborn errors of metabolism, including SBCAD deficiency. Identifying these mutationsearly allows for better management and intervention strategies.

‍

Newborn Screening Candidates

ACADSB is now included in many expanded newborn screening panels. Early screening can identify SBCAD deficiency in newborns, enabling doctors to provide timely treatment and dietary modifications that may reduce the risk of severe symptoms later in life.

Genetic Testing 

Genetic testing involves analyzing a person's DNA to identify specific mutations or genetic variations that may be linked to health conditions or diseases. This testing typically requires a sample of DNA, which can be obtained through blood, saliva, or cheek swabs. 

Once the sample is collected, it is processed in a laboratory to identify variations, such as single nucleotide polymorphisms (SNPs), that could impact a person’s health. Genetic testing is often used to assess disease risk, predict drug responses, and inform personalized treatment plans. 

Before testing, it's essential to consult with a healthcare provider to understand the purpose and implications of the test.

Genetic Testing for ACADSB

Genetic testing for ACADSB may be considered in individuals showing neurological symptoms, muscle weakness, or poor feeding, especially if there is a family history of SBCAD deficiency.

Testing a person's ACADSB genetic status helps identify mutations linked to SBCAD deficiency and similar metabolic conditions, allowing for early diagnosis and more effective management. It's especially useful for those with a family history of these disorders. 

Test ordering and interpretation are generally handled by a specialist; individuals with questions about this testing should consult a medical professional for more information.

By identifying mutations in the ACADSB gene, healthcare providers can offer targeted treatments and better understand the underlying causes of the symptoms. 

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.